Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 5/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289688 | 0.89 | ESR1 (0.60) | ESR1ESR2 | |
| SCHEMBL132494 | 0.81 | ESR2 (0.59) | ESR1ESR2PTGS2PTGS1KMT2A | |
| SCHEMBL5116818 | 0.80 | ESR1 (0.60) | ESR1ESR2MTNR1AMTNR1BKMT2A | |
| SCHEMBL5124386 | 0.80 | ESR1 (0.60) | ESR1ESR2MTNR1AMTNR1BKMT2A | |
| SCHEMBL5117049 | 0.79 | ESR1 (0.66) | ESR1ESR2 | |
| SCHEMBL18938578 | 0.77 | CES1 (0.62) | CES1SETD7CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL17152127 | 0.77 | ESR1 (0.69) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL8386622 | 0.76 | ESR1 (0.75) | ESR1ESR2 | |
| SCHEMBL11821605 | 0.75 | ESR1 (0.72) | ESR1MAOBEBPSIGMAR1 | |
| SCHEMBL8009481 | 0.74 | CES1 (0.59) | CES1SETD7CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369670-A1 | USE OF SWELL1 INHIBITORS AND MODULATORS TO TREAT TYPE 2 DIABETES AND OBESITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-12-02 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | CAMERON KIMBERLY O | 2010-12-16 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-4400543-A | ANTIFERTILITY AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-23 | — | — | US | disclosed |
| US-4323707-A | USEFUL FOR AMIMALS, AROYL-PHENYL-NAPHTHALENES OR DIHYDRONAPHTHALENES | ELI LILLY AND COMPANY (US) | 1982-04-06 | — | — | US | disclosed |
| US-4230862-A | 3-PHENYL-4-AROYL-1,2-DIHYDRONAPHTHALENES AND 1-ARYOYL-2-PHENYLNAPHTHALENES | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4075227-A | NONSTEROIDAL | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4075223-A | NONSTEROIDAL | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4017546-A | AROYL PHENYL INDENES AND AROYL PHENYL NAPHTHALENES | ELI LILLY AND COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | CES1 1162/4885ESR1 1/4885ESR2 3/4885 |
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | ESR1, GPER1, ESR2 | CES1 300/4885ESR1 1/4885ESR2 3/4885 |
| US-20210369670-A1 | USE OF SWELL1 INHIBITORS AND MODULATORS TO TREAT TYPE 2 DIABETES AND OBESITY | GPR119, GLP1R, SLC5A2 | CES1 188/4885ESR1 3510/4885ESR2 2357/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | CES1 1245/4885ESR1 1/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.